A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent

Grimes, Nathan; Tyson, Matthew; Hannan, Cathal John; Mulholland, Colin

doi:10.1016/j.clgc.2016.01.006

Cited by 16 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A summary of recent studies investigating the prognostic role of CRP level in UC is shown in Table . The cut‐off value for high versus low CRP level varied from 0.5 to 8 mg/dL.…”

Section: Serum Protein Markersmentioning

confidence: 99%

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

“…A summary of recent studies investigating the prognostic role of CRP level in UC is shown in Table . The cut‐off value for high versus low CRP level varied from 0.5 to 8 mg/dL.…”

Section: Serum Protein Markersmentioning

confidence: 99%

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Several studies investigating the role of NLR in patients undergoing treatment for metastatic RCC demonstrated patients with elevated NLR to have poorer prognosis. 3,12 The role of NLR in predicting prognosis in patients undergoing nephrectomy for RCC was investigated in a recent review 13 and identified only four studies. Only two of these studies reported on overall survival but both demonstrated elevated NLR to predict poorer prognosis.…”

Section: Introductionmentioning

confidence: 99%

The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma

Grimes

Hannan

Tyson³

et al. 2018

CUAJ

Self Cite

View full text Add to dashboard Cite

Introduction: Prognosis in patients with cancer is influenced by underlying tumour biology and also the host inflammatory response to the disease. There is limited evidence to suggest that an elevated neutrophil-lymphocyte ratio (NLR) predicts a poorer prognosis in patients undergoing nephrectomy for renal cell carcinoma (RCC). The aim of this paper is to investigate if patients undergoing nephrectomy for RCC with NLR ≤4 have a better overall and recurrence-free survival than patients with NLR >4. Methods: All patients who underwent nephrectomy at a single centre between January 1, 2011 and December 31, 2014 were identified. Patients were included if postoperative histology demonstrated RCC and if preoperative GPS was available. Patients were excluded if nephrectomy was not curative intent (i.e., cytoreductive nephrectomy), if primary tumour was graded to be T3b-4 disease, if there was presence of nodal or metastatic disease on preoperative staging, or if adequate followup notes were not available. Primary and secondary outcomes were overall survival and recurrence-free survival, respectively. Results: A total of 154 patients were included in analysis of overall survival; 146 patients were included in analysis of recurrence-free survival. Patients with NLR ≤4 had a much better overall survival than patients with NLR >4 (95% vs 78%; p=0.0219). Patients with NLR >4 also had higher rates of recurrence (p=0.0218). Conclusion: NLR may be a useful tool in identifying patients who may benefit from more frequent surveillance in the early postoperative period and may allow clinicians to offer surveillance schemes tailored to the individual patient.

show abstract

“…The inflammatory response in patients with malignancy plays an important role in cancer progression. Grimes et al (26) reported a systematic review of the prognostic role of inflammation in patients with localized RCC undergoing nephrectomy, recently. In their systematic review, they showed that elevated NLR to be associated with a poorer prognosis and they stated that evidence for PLR is minimal in this issue.…”

Section: Discussionmentioning

confidence: 99%

Platelet-to-lymphocyte ratio is an independent prognostic factor in clinically non-metastatic renal cell carcinoma

Canat¹,

Agalarov²,

Akkaş³

et al. 2017

Okmeydani Medical Journal

View full text Add to dashboard Cite

Objective: We aimed to investigate the prognostic significance of the preoperative platelet-to-lymphocyte ratio (PLR) in a cohort of clinically non-metastatic renal cell carcinoma (RCC). Material and Methods (HR, 3.460; 95% CI, p=0.001 Amaç: Operasyon öncesi trombosit/lenfosit oranı (TLO)'nın klinik non-metastatik renal hücreli kanser (RHK)'de prognostik öneminin araştırılması planlandı. Gereç ve Yöntem: RHK nedeniyle 2006 ve 2015 yılları arasında radikal veya parsiyel nefrektomi geçiren 298 hastanın retrospektif analizi yapıldı. TLO için optimal kestirim değeri "receiver operating curve" (ROC) analizi ile hesaplandı. TLO'nun prognostik önemi; Kaplan-Meier eğrileri, tek değişkenli ve çok değişkenli Cox regresyon modelleri ile değerlendirildi.Bulgular: TLO için ROC analizi ile optimal kestirim noktası 200 (AUC=0.715; sensitivite, %52,4; spesifite, %90,6) (HR,3,460; 95% CI,1, p=0,001

show abstract

A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent

Cited by 16 publications

References 19 publications

Role of systemic inflammatory response markers in urological malignancy

Role of systemic inflammatory response markers in urological malignancy

The role of neutrophil-lymphocyte ratio as a prognostic indicator in patients undergoing nephrectomy for renal cell carcinoma

Platelet-to-lymphocyte ratio is an independent prognostic factor in clinically non-metastatic renal cell carcinoma

Contact Info

Product

Resources

About